AB Dynamics plc (ABDP) — Investment Research Note

Executive summary

AB Dynamics designs, manufactures and services advanced testing, simulation and measurement products used by global automotive OEMs and regulators to develop and certify ADAS, autonomous driving, EV and vehicle-dynamics technology — sold across Testing Products, Testing Services and Simulation. Group revenue grew from £65m (FY21) to £115m (FY25) with adjusted operating margin expanding from 16.6% to 20.3%, before FY26 stepped sharply back to ~£92m and £18.3m adj operating profit as European OEM disruption, tariffs, a Middle East logistics shock and the VadoTech (China) contract termination collided with the "second-half-bias" trading pattern. The single most important valuation point today is that consensus adj operating profit has been reset from £24.4m (April 2026) to £18.3m (September 2026) while the share price has fallen from ~1465p to 856p — the question is whether the medium-term 10%/20%-margin growth compound is still achievable, and at what multiple.

Fair value estimate

• Methodology: primarily forward P/E on a normalised recovery scenario, cross-checked with EV/EBITDA.
• Central case: FY27E revenue ~£100m (order book already £31m into H1 FY27 2026-09 pre-close; eMpulse acquisition ~$5–8m contribution; VadoTech gone) at ~20% adj op margin → ~£20m adj op profit; ~£16m net income at ~18% effective tax rate (Patent Box relief) → adj diluted EPS ~68–72p.
• Multiple: 14–16x forward EPS is defensible for a capital-light, net-cash, ~20% ROCE market leader with structural ADAS/AV regulatory tailwinds; that yields a per-share range of ~950p – 1,150p and a fair value market cap of ~£218m – £263m (mid ~£240m).
• Cross-check (EV/EBITDA): FY27E adj EBITDA ~£24m, EV multiple ~9–10x → equity value ~£220–250m including £25m net cash.
• Vs latest disclosed market cap of £190.9m: upside of roughly +14% to +38%, mid-point ~+26%.
• Caveats: if FY27 profit sticks near the FY26 trough (£18m) the fair value collapses toward ~800p; if the 10%/>20% medium-term plan is delivered by FY28, upside to ~1,300p is plausible.

Sector context

• ICB classification "Automobiles and Parts" is technically correct given end-market, but ABDP is much closer to a specialised test-and-measurement / instrumentation supplier than a traditional auto components maker — higher gross margins (60%+), higher ROCE (~20%), net cash, and a fragmented, high-barrier competitive set.
• Quality/growth: above typical Consumer Discretionary/auto-parts peers; leverage profile is materially better (net cash vs. debt-laden auto suppliers).
• Listed comparators: Ricardo plc (engineering/testing services), Spectris (test & measurement instruments), Judges Scientific (scientific instrument roll-up). Direct pure-play peers are largely private (e.g. AVL, Horiba is closer but broader).

Investment thesis

• Structural regulatory tailwinds are intact and independent of the current European OEM turmoil: Euro NCAP 2026 protocols raise scenario count to >1,000; US mandates AEB on all light-duty passenger vehicles by 2029; commercial-vehicle testing is a net-new addressable market 2026-04 half-year. ABD's LaunchPad/GST/driving robots are Euro NCAP-approved testing tools — largely non-discretionary spend for OEMs and NCAP labs.
• Valuation now reflects a trough, not a bull case: the market cap of £190.9m equates to ~10.4x mid-cycle adjusted operating profit (£18.3m FY26) and ~8x on a recovered £24m FY28 case, versus historical multiples closer to 15–20x. The FY25 delivery (£23.3m adj op profit, +15% YoY, cash conversion 106%, ROCE 20.2%) is only one year old and demonstrates the platform's earnings power when order intake behaves 2025-11 final results. The pre-close confirmed FY26 in-line and net cash of £24.5m even after the eMpulse acquisition and Venshure earn-out 2026-09 pre-close.
• Balance-sheet optionality and disciplined M&A: £24.5m net cash plus a £20m undrawn RCF gives capacity to bolt on high-quality assets; eMpulse (Aug 2026) adds servoelectric NVH/durability lab equipment, complementing the SPMM, with expected FY27 earnings accretion 2026-08 eMpulse acquisition. Bolab and Venshure were similarly small, complementary and now-integrated 2025-11 final results.

Key risks

• European OEM cyclicality and geopolitical disruption are hitting revenue conversion right now — restructuring announcements, procurement delays, Middle East logistics headwinds, tariff-driven customer investment deferrals; ABDP has "healthy pipeline" but "lengthening decision timelines" 2026-07 trading update.
• Execution risk on leadership transition: long-serving CEO James Routh departed July 2025; CFO promoted to CEO Dec 2025; CFO role currently filled by an interim (Andrew Lewis) with a permanent search ongoing. VadoTech impairment (£16.8m) landed in H1 2026, showing that mis-scoped acquisitions can hurt 2026-04 half-year.
• Concentration in a single, cyclical end-market: ~100% automotive; ABD Solutions diversification (mining/construction/defence) is early-stage revenue; a global auto R&D spending contraction (recessionary or EV-transition-driven) has no easy offset. High-value SPMM and simulator orders are lumpy — one contract slip can move a quarter 2026-04 half-year.

Operating leverage

The business runs with a high fixed-cost base: 14 facilities in 6 countries, an R&D-heavy product roadmap, a new group ERP, and a corporate/regional-hub cost base largely uncorrelated with revenue in the short run. Gross margin of 62–64% 2025-11 final results, 2026-04 half-year combined with an ~£25m fixed overhead pool (from the operating profit bridge) implies strong operating leverage: each incremental £1 of revenue at 60%+ contribution margin should drop most of that to operating profit once fixed costs are covered. In FY26 this bit them the wrong way (revenue –16% H1, adj op profit –16%), but the same physics runs in reverse: on a plausible FY27 revenue recovery to £100m (+9% vs. FY26) with margin held at 20%, adj op profit rises ~10%; on a return to £115m (+25%), profit could rise ~30% to ~£24m. Management's own medium-term plan explicitly targets "10% organic growth and >20% margin" via operational gearing, supply chain gains and mix 2024-11 final results. Observable inflection points: SPMM and simulator deliveries are individually material (six-figure to low-seven-figure per unit), and the Simulation segment already showed –11% revenue but –540bps margin in FY25 — a live example of the leverage direction of travel.

Value-trap signals

• Repeated profit warnings in FY26: consensus adj op profit cut from £24.4m (April) to £18.3m (July/September) — a 25% reset in ~5 months; that is a material guidance miss, not just a "one-quarter" slip.
• VadoTech impairment (£16.8m in H1 2026) and full contract exit indicate that at least one recent acquisition became commoditised in <3 years — a signal to watch on future M&A.
• Sole customer >10% of revenue in FY25 (disclosed in final results) — some concentration on European OEM programmes now under stress.
• Auto end-market cyclicality and EV/ICE transition uncertainty — genuine structural risk, though partially offset by powertrain-agnostic positioning.
• Overall, this is not a classic value trap — no dividend cut (H1 2026 dividend +10%), no rising debt, no going-concern issues, no revenue in structural decline. It looks like a cyclical air-pocket in an otherwise good business.

Earnings vs. expectations

• FY25 (Nov 2025): guidance range £22.0–22.9m; delivered £23.3m adj op profit — beat ("slightly ahead of expectations").
• H1 2026 (April 2026): in line with prior guidance of ~£49m revenue; margin held at 18.6% despite revenue –16%. FY guidance reiterated at £24.4m adj op profit.
• July 2026 update: first material downgrade — FY26 revenue range £90-95m (from implied ~£125m), adj op profit implicitly £18–19m, VadoTech classified as discontinued.
• September 2026 pre-close: delivered £91.6m revenue and £18.3m adj op profit, in line with the reset July guide but a miss vs. the original FY26 plan.
• Pattern: multi-year beat-or-meet track record on the way up, then a sharp single-year cut in FY26 driven by external factors (tariffs, geopolitics, European OEM demand). Not a serial disappointer, but not immune to macro either.

Conviction

Rating: 3 (moderate). Anchoring factors: (i) clean, well-disclosed financials with granular segment data and explicit consensus references in every RNS; (ii) a five-year track record of double-digit revenue and profit growth with strong cash conversion; (iii) valuation is not stretched — the multiple compression already discounts a weak FY26. Limiting factors: (i) FY27 order intake and European OEM behaviour are genuinely uncertain — the fair value range widens materially if H1 FY27 disappoints; (ii) leadership transition (interim CFO, new CEO) introduces execution risk on the medium-term plan.

Driver scoring rationale

• ai_beneficiary (35): ABDP tests and validates ADAS/AV systems — some derived exposure to the autonomous-vehicle megatrend and simulation software (rFpro, AV Elevate) has AI-relevant use cases (synthetic training data), but this is a supplier to automotive R&D, not a picks-and-shovels play on the AI/data-centre build-out. Revenue growth is regulatory- and cycle-driven, not AI-capex-driven.
• operating_leverage (70): high gross margin (~62%), fixed R&D and central-cost base, SPMM/simulator revenues that are individually material — recovery scenarios generate meaningful profit multiples on relatively small revenue moves.
• earnings_surprise_trend (40): strong track record 2021–2025, then a material 25% cut to FY26 consensus in July 2026. Net: more recent misses than beats, tilting slightly below "in-line".
• cyclicality (65): automotive R&D is cyclical (though testing/certification is more resilient than build volumes); FY26 shows the exposure clearly.
• moat (65): market leader in a niche with regulatory-body-endorsed products (Euro NCAP-approved), long-standing OEM relationships, high customer switching costs (calibration, integration into test workflows), high technical barriers.
• leverage (10): net cash £24.5m, £20m undrawn RCF, cash conversion 100%+ — fortress balance sheet.
• earnings_quality (65): adjusted-to-statutory reconciliations are transparent but material (large amortisation of acquired intangibles and, in FY26, an £16.8m VadoTech impairment). Cash conversion is genuinely strong (102% rolling), which supports adjusted numbers.
• management_quality (60): long track record of disciplined M&A (Bolab, Venshure, eMpulse) and margin progression; VadoTech impairment and current leadership transition (interim CFO) are modest offsets.
• growth_momentum (35): revenue in FY26 is down ~20% YoY on a reported basis (up-restated), order book £31m entering FY27 is smaller than the £47m at H1 2026 — momentum is genuinely negative right now, though the medium-term drivers are intact.

Overall score rationale

The investor's three pillars: (a) AI-receiver — weak (score ~35 on AI beneficiary); (b) operating leverage — strong (70); (c) valuation discipline — good (~26% upside on a conservative recovery, trough multiple ~10x); plus (d) downside protection — very good (net cash, high-quality business model). The weak direct AI angle materially caps the overall score under the 35% AI weighting, notwithstanding all other pillars scoring well. Landing at ~480: an interesting quality name available at a fair price with genuine operating leverage to any recovery, but not the AI-receiver profile the strategy prioritises.